Clinical Trial

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

Study acronym: PROGRESS
Recruiting
View on ClinicalTrials.gov →
Summary
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Protocol Amendment History 39 amendments
This ClinicalTrials.gov record has been amended 39 times since 2021-05-12; most recent amendment 2025-12-12.
Status change: Active, Not Recruiting → Recruiting 2024-04-26
Status change: Recruiting → Active, Not Recruiting 2023-12-21
Status change: Not Yet Recruiting → Recruiting 2021-10-08
Trial Details
NCT Number NCT04889872
Lead Sponsor Edwards Lifesciences
Conditions Aortic Stenosis, Calcific, Aortic Valve Stenosis
Enrollment 2,250 participants
Start Date 2021-10-12
Primary Completion 2029-06 (estimated)
Study Completion 2037-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-17